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Background: In kidney transplantation, the prevalence of hypercholesterolemia as a co-morbidity factor known to
affect graft function, is rising due to the increased number of older donors in response to organ shortage as well as
to the hyperlipidemic effects of immunosuppressors in recipient. This study aimed to characterize the effects of
hypercholesterolemia on renal graft outcome, investigating the role of oxidized low-density lipoprotein (OxLDL).
Methods: In vivo, we used a porcine preclinical model of renal auto-transplantation modulated by two experimental
diets: a normal (n = 6) or a hyperlipidemic diet (n = 5) maintained during the 3 month follow-up after the surgical
procedure. Kidney function and OxLDL levels were monitored as well as fibrosis, LOX-1 and TGF beta signaling
pathways. In vitro, we used human artery endothelial cells subjected to OxLDL to investigate the TGF beta profibrotic
pathway and the role of the scavenger receptor LOX-1.
Results: Hyperlipidemic diet-induced increase in plasma OxLDL levels at the time of surgery correlated with an increase
in proteinuria 3 months after transplantation, associated with an early graft fibrosis combined with an activation of renal
TGF beta signaling. These data suggest a direct involvement of OxLDL in the hyperlipidemic diet-induced activation of
the pro-fibrotic TGF beta pathway which seems to be activated by LOX-1 signaling. These results were supported by
studies with endothelial cells incubated in culture medium containing OxLDL promoting TGF beta expression inhibited
by LOX-1 antibody.
Conclusions: These results implicate OxLDL in the hyperlipidemic diet-promoted fibrosis in transplanted kidneys,
suggesting LOX-1 as a potential therapeutic target and reinforce the need to control cholesterol levels in kidney
transplant recipients.
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In kidney transplantation, the prevalence of hypercholeste-
rolemia as a co-morbidity factor is rising due to the in-
creased number of older donors in response to organ
shortage as well as to the hyperlipidemic effects of immu-
nosuppressors in recipient [1,2]. In general, hypercholeste-
rolemia is associated with increased circulating levels of* Correspondence: t.hauet@chu-poitiers.fr
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unless otherwise stated.oxidized low density lipoproteins (OxLDL) [3]. These modi-
fied lipoproteins are involved in endothelial cell dysfunction
[4], the first cell type subjected to ischemia and reperfusion
injury (IRI) in organ transplantation.
In normocholesterolemic renal transplantation, endo-
thelial activation is involved in inflammation and fibrosis
development [5]. Despite the known deleterious effects
of hypercholesterolemia on endothelial cell function and
the importance of this cell type in IRI, few data are available
on the consequences of hypercholesterolemia during organ
transplantation [6]. In living-donor kidney transplantation,
donor hypercholesterolemia is associated with a reductionral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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transplantation, pre-transplant hypercholesterolemia in
the recipient increases the rate of acute rejections [8] and
the risk of late graft loss [9], whereas post-transplantation
hypercholesterolemia is associated with chronic allograft
dysfunction [10]. Bosmans et al. have previously suggested
a role of OxLDL in poor renal allograft outcome in hyper-
lipidemic recipients [11] indicating the possible involve-
ment of OxLDL in kidney IRI in hypercholesterolemic
conditions.
In the kidney, hyperlipoproteinemia and their subse-
quent oxidation are associated with glomerular capillary
dysfunction in rodents and severe glomerulosclerosis in
dyslipidemic patients due to lipid deposits in glomeruli
[12,13]. Experimental studies in pigs have demonstrated
that diet-induced hypercholesterolemia led to renal endo-
thelial dysfunction associated with vascular and micro-
vascular remodeling, inflammation, and kidney fibrosis
[14,15]. Thus, hypercholesterolemia can affect endothelial
cell function and accelerate tissue remodeling in the kidney
graft.
In atherosclerosis, the lectin-like OxLDL receptor-1
(LOX-1) plays a direct role in plaque formation [16].
This scavenger receptor is expressed on endothelial cells
[17], smooth muscle cells and macrophages [18]. In these
cells, binding of OxLDL to LOX-1 leads to reactive oxygen
species (ROS) generation combined with NFκB activation
[19] leading to oxidative stress and endothelial activation
[20]. In cardiac fibroblasts, LOX-1 activation has been
linked to collagen synthesis via an interaction between
LOX-1-NADPH oxidase-TGFβ (Transforming Growth
Factor beta) leading to an activation of the Mitogen-
activated protein kinase (MAPK) pathway [21] establishing
a possible link between the OxLDL signaling pathway and
irreversible tissue fibrosis.
Although dyslipidemia is recognized as a non-immunologic
factor negatively affecting early graft function [8], the con-
sequences on renal graft outcome remain to be clarified.
In this study, we hypothesized that a high-fat diet (HD),
started before transplantation and maintained after sur-
gery, increases circulating levels of OxLDL, affects
endothelial cell functions, and irremediably accelerates
interstitial fibrosis development in auto-transplanted
porcine kidneys.
Methods
Animal model and surgical procedures
Male Large White pigs were fed a standard (ND) or a
high-fat diet (HD, standard diet + 20% Lard and 2%
cholesterol) immediately after weaning and maintained
until euthanasia [14]. The renal auto-transplantation
model was performed when the animals reached 37-46 kg
(3 months old) as previously described in accordance with
the guidelines of the French Ministries of Agriculture andResearch, and the institutional committee for the use and
care of laboratory animals (CEEA Poitou-Charentes, project
reference number: CE2012-4) [5,22,23]. Briefly, the left
kidney was removed, flushed with 300 ml of UW preser-
vation solution and preserved at 4°C in the same solution
in static conditions for 24 hours. On the day of transplan-
tation, the right kidney was removed and the left kidney
grafted mimicking the nephron mass in the transplanted
situation. Two experimental groups were studied: ND+Tx:
transplanted kidneys removed 3 months after surgery from
animals fed a standard diet (n = 6), HD+Tx: transplanted
kidneys removed 3 months after surgery from animals fed a
high-fat diet (n = 5). One transplanted HD pig died before
completion of the study due to surgical complications and
was not included in data analysis. Plasma creatinine,
cholesterol and urinary proteins were measured using an
automatic analyzer (Modular, Roche Diagnostic, France).
OxLDL (Diasorin, Antony, France) and superoxide dis-
mutase (SOD) activity (Cayman, Montigny Le Bretonneux,
France) were measured in plasma.
Immunohistopathological studies
Paraffin-embedded sections (3 μm) of renal cortical samples
were examined under blinded conditions by a pathologist
and a nephrologist. As described previously, the level of
tubulo-interstitial fibrosis were investigated using Sirius
red staining [24] and tissue remodeling by immuno-
histochemical assessment of vimentin expression (1/500,
Cell Marque, Rocklin, CA, USA).
Frozen cortex sections (5 μm) were used to investigate
LOX-1 and TGFβ expression by double immunofluores-
cence localization. We used a rabbit primary antibody at
1/100 (Abcam, Paris, France) and a goat anti-rabbit
secondary antibody coupled to Alexa 488 fluorochrome
(1/1000, Life Technologies, Saint Aubin, France) for LOX-
1 expression and a mouse primary antibody at 1/100 (Santa
Cruz, CA, USA) and a goat anti-mouse secondary antibody
coupled to Alexa 568 Fluorochrome (1/1000, Life Tech-
nologies) for TGFβ.
Western blotting procedure
A standard Western blotting protocol was used as de-
scribed previously [5,25] with antibodies against TGFβ
(1:600), matrix metalloproteinase 2 (MMP2, 1:200) (Santa
Cruz, CA, USA); connective tissue growth factor (CTGF,
1:500) (Biovision, Mountain View, CA, USA), LOX-1
(1:1000) (R&D System), bone morphogenetic protein-7
(BMP-7, 1:5000) (AbDSerotec, Minneapolis, MN, USA),
nuclear factor-kappa B (NFκB, 1:1000), its inhibitor kappa
B alpha (IκBα, 1:200), Phospho-P38 (1:1000) (Millipore,
Billerica, MA, USA), NADP(H) oxidase subunit Gp91phox
(1:500, BD Transduction Laboratories, France). Loading
controls were β actin (1:3000, Sigma Aldrich, France)
or P38 (1:1000, Millipore). Appropriate HRP-coupled
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France) were used to detect the band by chemilumines-
cence with ECL plus (GE Healthcare, France). Intensities
of the protein bands were determined and quantified using
AlphaEase FC software (Alpha Innotech Corporation, San
Leandro, CA).
Human LDL purification and oxidation
Human LDL were isolated by sequential ultracentrifugation
and oxidized by UV-C irradiation as previously described
[26]. LDL oxidation level was verified by quantification of
the thiobarbituric-acid reacting substances (TBARS) [27].
This oxidation protocol led to an average TBARS concen-
tration of 14.28 ± 2.21 μM.
In vitro incubation of OxLDL on human aortic endothelial
cells: effect of LOX-1 antibody
Human aortic endothelial cells (HAEC), obtained from
Gibco (France), were cultured with M200 medium (Gibco)
supplemented with 10% fetal bovine serum (Invitrogen,
France) in a humidified atmosphere at 5% CO2 and 37°C.
The cells were used for the experiments after 4 to 5 pas-
sages. For the time course of 24 h, OxLDL’s effects on
LOX-1 and TGF β protein expressions were evaluated in
HAECs treated with culture medium supplemented or not
with OxLDL (25 μg/mL) [28,29]. We also evaluated TGFβ
secretion in culture medium with a Duoset Elisa kit from
R&D System (France). The effect of LOX-1 antibody (R&D
System), selected for its ability to block receptor-ligand
interaction, was tested in these different experimental
conditions.
Statistical methods
Results are shown as mean ± SEM. We used a student
t-test for two-group comparisons or a Mann–Whitney
test when the variance was not equal between the groups.
Correlation studies were performed using linear regression.
All statistical analyses were performed using the NCSS
Software (Version 07.1.20, Kaysville, UT, USA). Statistical
significance was accepted for p < 0.05.
Results
High-fat diet promoted increases in plasma OxLDL levels,
worsened proteinuria but did not affect creatinine
excretion recovery after kidney transplantation
Although swine body weights were not significantly differ-
ent between the groups on the day of surgery, HD animals
exhibited a higher body weight at the end of the exper-
iments (Table 1, p < 0.05). After renal transplantation,
plasma cholesterol levels were significantly increased in the
HD+Tx group after the first week following transplan-
tation (p < 0.05) and were further elevated 3 months post-
transplantation (Figure 1A). In the HD+Tx animals plasma
levels of OxLDL remained statistically more elevated at day1 and 3 months after surgery in comparison with the ND+
Tx animals (p < 0.05, Figure 1B). This enhanced oxidative
stress in the HD+Tx group was supported by a concomi-
tant decrease in plasma SOD activity by 3 months (p < 0.05,
Figure 1D, Table 1). In terms of kidney function, although
serum creatinine increased after transplantation, there was
no statistical difference among groups in its peak levels or
recovery profile (Figure 1C). Similarly, diuresis recovery
was not different between the two groups (Table 1). HD
pigs exhibited elevated proteinuria 3 months after reperfu-
sion compared to ND pigs (p < 0.05, Figure 2A). Linear
regression analysis revealed a significant correlation be-
tween the circulating levels of OxLDL measured at day 1
post-surgery and the proteinuria determined at 3 months
(r2 = 0.91, p = 0.01) in the HD group only (Figure 2B).
These results suggest that OxLDL may be linked to renal
graft survival and function.
HD concomitantly activated LOX-1 and TGFβ pathways
As mentioned above, HD animals presented, during the
post-surgical follow-up, elevated plasma OxLDL levels in
comparison to ND animals (p < 0.05, Figure 1B). This
pro-oxidative milieu was accompanied in kidney graft,
3 months after surgery, by significant increases in pro-
fibrotic TGFβ (p < 0.05) and its downstream effector CTGF
(p < 0.05) protein levels and decreases in protein levels of
the anti-fibrotic factor BMP-7 (2-fold, p < 0.05, Figure 2C).
In addition, reduced Pro-MMP2 protein levels (an enzyme
degrading the extracellular matrix) (p < 0.05) were observed
in HD+Tx in comparison to ND+Tx animals (Figure 2C).
The increase in circulating OxLDL levels in the HD+Tx
group was accompanied by 2 fold- and 1.5- fold-
upregulations of LOX-1 and Gp91phox protein levels
respectively (p < 0.05 vs ND + Tx, Figure 2D). This was
associated with significant increases in the expression
of LOX-1 downstream effectors including NFκB and P38
proteins (p < 0.05) and a 4-fold decrease in the expression
of the NFκB inhibitor Iκb-α (p < 0.05, Figure 2D), all of
which have been implicated in the LOX-1 signaling path-
way [21]. These observations suggest that a hyperlipidemic
diet under our experimental conditions induced concomi-
tant increases in oxidative stress and pro-fibrotic pathway
signaling potentially stimulating fibrosis development after
transplantation.
HD promoted kidney graft fibrosis and tissue remodeling
Three months after transplantation, red Sirius staining
showed that HD+Tx cortex presented a 3-fold increase in
fibrosis in comparison with the ND+Tx animals (p < 0.001,
Figure 3A). Furthermore, HD +Tx pigs exhibited a higher
number of vimentin-positive tubules supporting tissue
remodeling (Figure 3B). Immunofluorescence experiments
revealed that LOX-1 was localized mainly on vascular
structures and glomeruli in the kidneys independently of
Table 1 Kidney function and blood metabolites of transplanted animals fed a normal or a high-fat diet
Day 0 M3
Normal diet High-fat diet Normal diet High-fat diet
Body weight (Kg) 42.3 ± 1.2 40.9 ± 0.9 109.3 ± 3.8 129.0 ± 2.9*
Diuresis (ml/24 h) 2867 ± 145 2567 ± 88 3416 ± 487 2166 ± 364
Creatininemia, (μmol/L) 95 ± 2 99 ± 5 197 ± 22 184 ± 6
Plasma SOD activity (U/mL) 10.3 ± 3.9 10.9 ± 3.0 37.9 ± 7.4 22.2 ± 7.7*
*p < 0.05 vs Normal diet.
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observed, by confocal analysis a co-localization of LOX-1
and TGFβ around peritubular capillaries 3 months after
surgery independently to the diet (Figure 5). These data
support the stipulation that HD promotes graft fibrosis
and suggests interplay between OxLDL-LOX-1 and TGFβ.
LOX-1-blocking antibody inhibited the OxLDL-induced
TGFβ secretion in HAEC
To evaluate the direct role of OxLDL in the HD-induced
TGFβ overexpression observed in vivo in fibrotic kidney
graft, we treated HAECs with OxLDL. OxLDL treatment
led to respectively 1.6- and 3-fold increases in LOX-1
and TGFβ protein levels in comparison to PBS treated cells
(p < 0.05, Figure 6A). This was associated with a 1.8-fold in-
crease in TGFβ levels in the culture medium (Figure 6B).
Addition of LOX-1-blocking antibody in the medium prior
to OxLDL treatment prevented the OxLDL-mediated
induction of TGFβ secretion (Figure 6B). This abolitionFigure 1 High-fat diet increased plasma cholesterol and OxLDL levels
cholesterol levels measured on the day of transplantation (D0) and after su
B) Time course evolution of plasma OxLDL levels. High-fat diet did not chang
C) Time course evolution of plasmatic creatinine measured on the day of tran
plasma SOD activity. Values significantly different from the normal diet group
p < 0.05; ††: p < 0.01; †††: p < 0.001.of OxLDL-induced TGFβ secretion in vitro suggests a
direct effect of OxLDL on TGFβ production via LOX-1,
offering a plausible hypothesis to explain the increase in
cortical TGFβ levels observed in transplanted animals
fed a hyperlipidemic diet.
Discussion
We demonstrated that diet-induced hypercholesterolemia
was associated with significant increases in circulating
levels of OxLDL. These HD-induced increases were not
associated with alterations in kidney function recovery
after transplantation but led to a 2.5-fold increase in the
interstitial fibrosis extent and enhanced proteinuria
3 months after surgery in the hypercholesterolemic animals.
This increased fibrosis extent, in the HD-animals, was
linked to concomitant activations of TGFβ and LOX-1
signaling pathways, suggesting a probable association of
the OxLDL-LOX-1 in tissue fibrosis development. Immu-
nohistochemical studies revealed that LOX-1 expressionin transplanted pigs. A) Time course evolution of plasmatic total
rgery, in pigs fed either a normal (white) or a high-fat diet (grey);
e graft function recovery assessed by plasma creatinine level monitoring,
splantation (D0) and after surgery; D) Time course determination of
are indicated by *: p < 0.05; **: p < 0.01 and from the D0 time point by †:
Figure 2 High-fat diet was associated with a greater proteinuria and with LOX-1 and TGFβ pathways activation in renal cortex
3 months after transplantation. A) Proteinuria levels in the two experimental groups 3 months after surgery; Values significantly different from
the normal diet group are indicated by ***: p < 0.001; B) Linear regression of the plasmatic OxLDL levels measured at D1 and the proteinuria
determined at M3 in the normal diet group (Left panel) and the high-fat diet group (Right Panel). The straight line represents the regression curve
and dotted lines represent the 95% confidence interval; C) Immunoblots and densitometric quantification of TGFβ signaling (TGFβ, CTGF, BMP-7)
and matrix homeostasis (pro-Matrix Metalloproteinase 2, pro-MMP2); and D) LOX-1 intracellular signaling (Gp91phox NADPH oxidase subunit,
NFκB-IκBα, PhosphoP38) in renal cortex. Values significantly different from the normal diet group are represented by *: p < 0.05.
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the endothelium involving endothelial cells in the HD
effect. The hypothesis of a direct involvement of the
OxLDL-LOX1 signaling pathway in the activation of
the TGFβ signaling pathway in the pro-fibrotic kidney
graft is suggested by in vitro results demonstrating that
blocking LOX-1 prevented the OxLDL-induced increase
in TGFβ secretion by arterial endothelial cells. Taken
together, the increased fibrosis extent and over activation
of TGF-β signaling pathway in hypercholesterolemic con-
ditions suggest a poor long-term graft outcome in the
HD animals.
Hypercholesterolemia increases LDL susceptibility to
oxidation [30] and therefore production of plasmatic
OxLDL [31,32]. Diet-induced increases in circulating levels
of OxLDL have been reported in pigs in the past [33]. Inthis study, we hypothesized that OxLDL could directly
exacerbate fibrosis injuries in kidney graft. Transplanted
kidney was exposed to fibrosis tissue spread which pro-
motes a hypoxic milieu due to capillary rarefaction as
well as alterations in oxygen diffusion capacity which is
an additional cause of fibrosis. To assess this hypothesis,
we compared in vitro the effects of OxLDL exposure on
endothelial cells. OxLDL exposure induced TGF-β protein
expression and enhanced endothelial LOX-1 expression.
In vivo, we investigated in pigs, fed with either a normal
or a high-fat diet, the levels of plasma OxLDL during the
first three months of graft follow-up. After transplantation
in normocholesterolemic conditions, pigs exhibited a
significant increase in plasmatic OxLDL levels at day 1
and 30 as previously reported for kidney IR in rodents
[34] or suggested in human kidney transplantation by the
Figure 3 High-fat diet increased renal interstitial fibrosis extent and the number of vimentin positive tubules. Representative pictures
(200X) of typical Sirius red staining (A) in transplanted pigs fed a normal or a high-fat diet. Histogram represents the percentage of fibrosis extent.
Values significantly different from the normal diet group are represented by ***: p < 0.001. B) Representative pictures (200X) of vimentin staining
revealed by diaminobenzidinine immunohistochemistry in transplanted pigs fed a normal or a high-fat diet. Arrows indicate glomerulus (Gl),
tubules (Tl) and vimentin (Vim) localization. Histogram represents the quantification of the number of vimentin-positive tubules. Values significantly
different from the normal diet group are represented by *: p < 0.05.
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These increases in plasma OxLDL levels are in accordance
with the well-characterized oxidative stress induced by the
ischemia-reperfusion sequence in normocholesterolemic
conditions [36]. In hypercholesterolemic animals, plasma
OxLDL and SOD levels were further elevated and de-
creased respectively during the 3 months post-surgery
indicating a greater oxidative stress in these animals.
Oxidative stress is one of the major deleterious mecha-
nisms involved in IRI and delayed graft function [37-39].
In addition, HD did not significantly alter kidney functionFigure 4 Immunofluorescence localization of LOX-1 in the endothelium
localization of LOX-1 in kidney cortical samples 3 months after transplantationrecovery evaluated by creatininemia or diuresis during the
3-month follow-up period despite a greater graft fibrosis
in comparison to ND animals. This absence of correlation
between early graft function and fibrosis extent occurs
also in the clinic [40]. Prevalence of interstitial fibrosis and
tubular atrophy has been reported to be 25% at 3 months
and 50% at 2 years in 41 patients with normal graft func-
tion [41]. Nonetheless, graft fibrosis has been reported to
reduce long-term graft survival [40]. The 3-month follow-
up in the present work is likely too short to observe an
impact of HD on basal kidney function.of intrarenal arteries. Representative pictures of immunofluorescence
in animals fed either a normal or a high-fat diet.
Figure 5 Confocal analysis of TGFβ and LOX-1 expressions. Representative pictures of double immunofluorescence localization of LOX-1
(green) and TGFβ (red) in kidney cortical samples 3 months after transplantation in animals fed either a normal or a high-fat diet (Magnification
x20). Colocalization of TGFβ and LOX-1 expressions (yellow) was observed around peritubular capillaries by confocal microscopy. Nuclei were
stained with DAPI (Blue).
Figure 6 LOX-1 antibody blocked TGFβ secretion induced by OxLDL in human artery endothelial cells. A) Effects of OxLDL
incubation during 24 h in endothelial cells on LOX-1 and TGFβ protein expressions, and B) on TGFβ secretion in culture medium
supplemented with OxLDL with or without neutralizing antibody against LOX-1 (results obtained from two independent experiments).
Values significantly different from the culture medium without OxLDL are indicated by †: p < 0.05; and from the culture medium without LOX-1
antibody by $: p < 0.05.
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Figure 7 Proposed mechanism of diet-induced fibrosis in
transplanted kidneys. In normocholesterolemic condition,
transplantation leads to an increase in TGFβ levels resulting in an
increase in vimentin positive tubules and collagen production which
are both involved in fibrosis development. Data from this study
indicate that the increase in plasma OxLDL levels induced by high-fat
diet leads to LOX-1 pathway activation by ligand fixation and promotes
an increase in LOX-1 protein content via either Ox-LDL alone or TGFβ
stimulation in artery endothelial cells, which in turn over-activates
the TGFβ signaling pathway. This activation acts in synergy with
transplantation to increase fibrosis development.
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OxLDL, evaluated one day after transplant surgery, were
significantly correlated with the proteinuria present 3 months
later, suggesting a detrimental role of OxLDL on graft out-
come. Plasma OxLDL levels may be a relevant parameter
to monitor just after transplantation in the recipient to
predict graft outcome. Also, this suggests that therapeutic
interventions aimed at reducing the levels of these modi-
fied lipoproteins in the recipient should be started as early
as possible. Fibrosis is considered to be the major process
leading to renal graft loss. The involvement of TGFβ and
its signaling pathway in the etiology of kidney graft fibrosis
is well characterized [42-44]. In the present study, the
HD-associated increase in fibrosis may be linked to the
elevated levels of plasma OxLDL. Indeed, Hu et al. have
established a link between LOX-1-NADPH oxidase and
the TGFβ-mediated collagen synthesis in cardiac fibroblasts
[21]. In vivo, the direct involvement of LOX-1 in IRI and
remodeling has been previously reported in normocho-
lesterolemic mouse hearts [45,46]. In the present work,
HD + Tx induced concomitant increases in LOX-1 and
TGFβ signaling pathways represented by NFκB, phos-
pho P38 and the gp91phox NAD(P)H oxidase subunit
up-regulations and decreased IκB expression for the
LOX-1 signaling pathway and by TGFβ and CTGF up-
regulations as well as BMP-7 and Pro-MMP2 down-
regulations for the TGFβ signaling pathway indicating a
reduced capacity for matrix degradation giving rise to a
pro-fibrotic milieu. TGFβ is a pivotal growth factor in-
volved in several processes linked to IRI and fibrosis. The
parallel increases in collagen and vimentin expressions in
our study may partially be explained by TGFβ involvement
in vimentin expression, a mesenchymal cell marker, indicat-
ing tissue remodeling and dedifferentiation of tubular cells
towards mesenchymal cell types leading to fibrosis [47].
These observations suggest a poor outcome of kidney graft
in high-OxLDL conditions.
These data suggest that an association between OxLDL,
LOX-1 and TGFβ is present in HD-grafted kidneys. LOX-1
can be viewed as a mediator of endothelial dysfunction
[48]. Immunofluorescent staining in transplanted kidneys
revealed an intense expression of LOX-1 in the endothe-
lium of intrarenal arteries as previously shown in hyperlip-
idemic pig kidneys [49-51]. These results were supported
by colocalization of TGFβ and LOX-1 expressions around
peritubular capillaries. To characterize the role of OxLDL
in fibrosis development observed in vivo, we investigated
the direct involvement of LOX-1 in the TGFβ pathway
in arterial endothelial cells : the first target of ischemia
reperfusion injury in solid organ transplantation. A culture
medium supplemented with OxLDL induced, in endothelial
cells, concomitant overexpressions of TGFβ and LOX-1
proteins levels. Both OxLDL and TGFβ have been shown
to induce LOX-1 expression [21,52-54] and in this caseincreased LOX-1 expression could be mediated either
directly by Ox-LDL or indirectly via an Ox-LDL-induced
increase in TGFβ. Nonetheless, blocking human LOX-1
with an antibody prior to OxLDL addition prevented the
increase in TGFβ secretion in the culture medium sup-
porting the stipulation that induction of TGFβ expression
was the consequence of LOX-1 activation by the Ox-LDL
in this in vitro setting. The proposed mechanism of diet-
induced fibrosis in transplanted kidneys is summarized in
Figure 7. Briefly, in normocholesterolemic conditions,
the transplantation process leads to an increase in TGFβ
levels resulting in an increase in vimentin positive tubules
and collagen production which are both involved in fibrosis
development as previously described in our model [55]. In
case of a high-fat diet, the increase in plasma OxLDL levels
leads to LOX-1 pathway activation by ligand fixation and
promotes increase in LOX-1 protein content via either
Ox-LDL alone or TGFβ stimulation in artery endothelial
cells which in turn over-activates the TGFβ signaling path-
way. This activation acts in synergy with the transplantation
process to increase fibrosis. This proposed mechanism in-
volving a direct relationship between LOX-1 and fibrosis
development is supported by recent reports indicating that
LOX-1 abrogation reduced tissue remodeling in mice heart
[56] and kidneys [57].
Our study was limited by the use of young pigs with a
short term high-fat diet started before surgery, and by the
relatively short duration of the post-transplant follow-up
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renal transplantation is not only associated with dyslip-
idemia but also with immunosuppressor therapy or other
concurrent or pre-existing pathophysiological conditions
such as hypertension or diabetes which impair the renal
microvasculature and likely modulate its response to trans-
plantation. Nevertheless, the renal structure and function in
the swine model are similar to human kidneys [58], and
our results bear relevance and may shed light on the short-
term negative impact of diet-induced increase in OxLDL
circulating levels on renal IRI following transplantation.
In addition, our model is characterized by a relatively
short-term exposure to hypercholesterolemia and by the
absence of chronic vascular injury. To our knowledge,
this study is the first to report, in a large animal model,
a link between hypercholesterolemia and fibrosis deve-
lopment in kidney transplantation involving OxLDL and
the LOX-1 receptor, highlighting a pathophysiological
mechanism starting at an early stage, in the absence of
chronic injury and without detectable change on the mo-
nitoring of the renal function. In humans, the benefits of
cholesterol lowering therapy have been investigated in a
randomized control trial [59]. This study revealed that
treatment of renal graft recipient with fluvastatin, starting
5 years after transplantation, did not improve graft function
or graft loss even though there was a significant reduction
in the risk of cardiac death [60]. Taking into account the
early changes supported by this study in pigs, the fluvastatin
treatment in this clinical trial may need to be initiated
earlier to prevent the deleterious consequences of hyper-
cholesterolemia. These observations strongly suggest that
cholesterol lowering- or LOX-1 blocking therapies should
be initiated as early as possible in kidney graft recipients.
This study supports the assessment of these therapeutic
strategies in humans or in large animal models. Such pre-
clinical models are of interest because they allow a rapid
transfer for clinical application. Complementary studies
are warranted to focus on the effect of HD in donors
and consequences in recipient.
Conclusion
The significant correlation between plasma OxLDL and
proteinuria observed in the present work, as well as the
concomitant activation of LOX-1 and TGFβ signaling
pathways in vivo and the direct interaction between LOX-1
and TGFβ secretion in vitro, implicate OxLDL in the HD-
induced fibrosis and tissue remodeling observed as early
as 3 months after renal transplantation. Taken together,
these results suggest that diet could affect graft out-
come, identify LOX-1 as a therapeutic target of interest
and emphasize the need to better control either choles-
terol or OxLDL plasma levels in recipient with dietetic
and therapeutic measures at the early stage of renal
transplantation.Abbreviations
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